AGM
DYN icon

Alpine Global Management’s Dyne Therapeutics DYN Stock Holding History

Alpine Global Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,460
Closed -$440K – 242
2024
Q2 		$440K Buy
+12,460
New +$362K 0.08% 193

Other funds holding DYN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Alpine Global Management's DYN Position: Q3 2024 in Review

Alpine Global Management sold out of Dyne Therapeutics (DYN) in Q3 2024, closing a stake of 12,460 shares — an estimated $440K sold.

Alpine Global Management first reported a position in DYN in Q2 2024 and held it in 1 quarter. The position peaked at $440K in Q2 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q3 2024.

  • Alpine Global Management reported no remaining Dyne Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 12,460 Dyne Therapeutics shares in Q3 2024, an estimated $440K.
  • Alpine Global Management first reported a position in Dyne Therapeutics in Q2 2024 and held it in 1 quarter.
  • Alpine Global Management's Dyne Therapeutics position peaked at $440K in Q2 2024.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.